SeaStar Medical Holding Corporation(ICU)Earnings, Financials & Key Ratios
ICU•NASDAQ
$4.86
$29M mkt cap·Price updated May 7, 2026
AboutSeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.Show more
- Revenue$135K
- EBITDA-$25M-12191.5%
- Net Income-$25M+5.3%
- EPS (Diluted)-6.63+78.1%
- Gross Margin100%
- EBITDA Margin-18209.63%
- Operating Margin-13216.3%
- Net Margin-18392.59%
- Interest Coverage-73.12-456.3%
ICU Key Insights
SeaStar Medical Holding Corporation (ICU) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 99 (top 1%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ICU Price & Volume
SeaStar Medical Holding Corporation (ICU) stock price & volume — 10-year historical chart
Loading chart...
ICU Growth Metrics
SeaStar Medical Holding Corporation (ICU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM1195.59%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM54.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM86.88%
Return on Capital
10 Years-352.82%
5 Years-352.82%
3 Years-
Last Year-
ICU Peer Comparison
SeaStar Medical Holding Corporation (ICU) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 TPVG | 242.54M | 5.99 | 4.91 | 36.55% | -3.39% | 1.33 | ||
 AKBA | 316.54M | 1.18 | -56.73 | 47.46% | -8.83% | -62.72% | 6.63 | |
 CPRX | 3.82B | 31.17 | 18.55 | 19.78% | 36.39% | 22.46% | 0.00 | |
 XOMA | 489.66M | 41.29 | 28.28 | 83.06% | 56.4% | 31.88% | 1.57 | |
 KRMD | 206.52M | 4.44 | -77.76 | 22.23% | -5.27% | -13.61% | 0.21 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 BAX | 9.04B | 17.51 | -10.01 | 5.72% | -9.7% | -16.5% | 1.64 |
Compare ICU vs Peers
SeaStar Medical Holding Corporation (ICU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ICU Income Statement
SeaStar Medical Holding Corporation (ICU) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 135K | 881K |
| Revenue Growth % | - | - | - | - | - | 1195.59% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 41K |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 135K▲ 0% | 840K▲ 0% |
| Gross Margin % | - | - | - | - | 100% | 95.35% |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 6.45M | 4.45M | 11.61M | 14.21M | 17.98M | 14.76M |
| OpEx % of Revenue | - | - | - | - | 13316.3% | - |
| Selling, General & Admin | 2.43M | 1.68M | 6.92M | 8.04M | 8.87M | 6.71M |
| SG&A % of Revenue | - | - | - | - | 6571.85% | - |
| Research & Development | 4.03M | 2.77M | 2.5M | 5.97M | 9.11M | 8.06M |
| R&D % of Revenue | - | - | - | - | 6744.44% | - |
| Other Operating Expenses | 0 | 0 | 2.19M | 200K | 0 | 0 |
| Operating Income | -6.45M▲ 0% | -4.45M▲ 31.1% | -11.61M▼ 160.9% | -14.21M▼ 22.4% | -17.84M▼ 25.6% | -13.92M▲ 0% |
| Operating Margin % | - | - | - | - | -13216.3% | -1580.48% |
| Operating Income Growth % | - | 31.06% | -160.94% | -22.41% | -25.56% | - |
| EBITDA | 0 | -4.38M | -11.56M | -200K | -24.58M | -14.34M |
| EBITDA Margin % | - | - | - | - | -18209.63% | -1628.04% |
| EBITDA Growth % | - | - | -163.6% | 98.27% | -12191.5% | 51.53% |
| D&A (Non-Cash Add-back) | 6.45M | 0 | 0 | 14.01M | 0 | -246K |
| EBIT | -6.45M | -4.38M | -11.56M | -25.15M | -24.58M | -13.64M |
| Net Interest Income | -3.31M | -212K | -629K | -1.08M | -143K | 154K |
| Interest Income | 0 | 0 | 630 | 0 | 101K | 219K |
| Interest Expense | 3.31M | 212K | 630K | 1.08M | 244K | 65K |
| Other Income/Expense | 3.19M | -148K | -580K | -12.02M | -6.99M | 262K |
| Pretax Income | -3.27M▲ 0% | -4.6M▼ 40.7% | -12.19M▼ 165.2% | -26.23M▼ 115.2% | -24.83M▲ 5.4% | -13.66M▲ 0% |
| Pretax Margin % | - | - | - | - | -18390.37% | -1550.74% |
| Income Tax | 9K | -1K | 1K | 0 | 3K | 3K |
| Effective Tax Rate % | -0.28% | 0.02% | -0.01% | 0% | -0.01% | -0.02% |
| Net Income | -3.28M▲ 0% | -4.6M▼ 40.3% | -12.19M▼ 165.2% | -26.23M▼ 115.2% | -24.83M▲ 5.3% | -13.66M▲ 0% |
| Net Margin % | - | - | - | - | -18392.59% | -1551.08% |
| Net Income Growth % | - | -40.29% | -165.23% | -115.19% | 5.34% | 54.88% |
| Net Income (Continuing) | -3.28M | -4.6M | -12.19M | -26.23M | -24.83M | -13.66M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.01▲ 0% | -8.81▼ 88000.0% | -23.38▼ 165.4% | -30.26▼ 29.4% | -6.63▲ 78.1% | -0.52▲ 0% |
| EPS Growth % | - | -88000% | -165.38% | -29.44% | 78.09% | 86.88% |
| EPS (Basic) | -0.01 | -8.81 | -23.38 | -30.26 | -6.63 | - |
| Diluted Shares Outstanding | 521.64K | 521.64K | 521.34K | 866.81K | 3.74M | 26.39M |
| Basic Shares Outstanding | 521.64K | 521.64K | 521.32K | 866.81K | 3.74M | 26.39M |
| Dividend Payout Ratio | - | - | - | - | - | - |
ICU Balance Sheet
SeaStar Medical Holding Corporation (ICU) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 2.91M | 601K | 1.52M | 2.31M | 3.77M | 14.87M |
| Cash & Short-Term Investments | 2.81M | 510K | 47K | 176K | 1.82M | 13.76M |
| Cash Only | 2.81M | 510K | 47K | 176K | 1.82M | 13.76M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 58K | 0 | 0 | 112K | 221K |
| Days Sales Outstanding | - | - | - | - | 302.81 | 68.36 |
| Inventory | 55K | 0 | 0 | 0 | 0 | 83K |
| Days Inventory Outstanding | - | - | - | - | - | 454.02 |
| Other Current Assets | 0 | 0 | 12K | 0 | 0 | 807K |
| Total Non-Current Assets | 2K | 2K | 1.52M | 1.21M | 892K | 656K |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2K | 2K | 1.52M | 1.21M | 892K | 3.1M |
| Total Assets | 2.91M▲ 0% | 603K▼ 79.3% | 3.04M▲ 403.8% | 3.51M▲ 15.6% | 4.66M▲ 32.6% | 15.53M▲ 0% |
| Asset Turnover | - | - | - | - | 0.03x | 0.10x |
| Asset Growth % | - | -79.27% | 403.81% | 15.64% | 32.59% | 411.18% |
| Total Current Liabilities | 1.08M | 3.12M | 16.15M | 13.05M | 6.84M | 4.07M |
| Accounts Payable | 382K | 85K | 1.93M | 4.37M | 3.05M | 2.02M |
| Days Payables Outstanding | - | - | - | - | - | 25.86K |
| Short-Term Debt | 20K | 2.38M | 1.18M | 4.74M | 574K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 471K | 10.8M | 2.41M | 33K | 2.05M |
| Current Ratio | 2.69x | 0.19x | 0.09x | 0.18x | 0.55x | 0.55x |
| Quick Ratio | 2.64x | 0.19x | 0.09x | 0.18x | 0.55x | 0.55x |
| Cash Conversion Cycle | - | - | - | - | - | -25.34K |
| Total Non-Current Liabilities | 73.41M | 299K | 7.65M | 4.34M | 0 | 0 |
| Long-Term Debt | 63K | 244K | 7.65M | 4.34M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 73.35M | 55K | 0 | 0 | 0 | 0 |
| Total Liabilities | 74.49M | 3.42M | 23.8M | 17.38M | 6.84M | 4.07M |
| Total Debt | 83K | 2.62M | 8.83M | 9.08M | 574K | 0 |
| Net Debt | -2.72M | 2.11M | 8.78M | 8.9M | -1.25M | -13.76M |
| Debt / Equity | - | - | - | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | 0.96x |
| Interest Coverage | -1.95x | -20.99x | -18.43x | -13.15x | -73.12x | -209.88x |
| Total Equity | -71.58M▲ 0% | -2.82M▲ 96.1% | -20.76M▼ 637.3% | -13.87M▲ 33.2% | -2.18M▲ 84.3% | 11.46M▲ 0% |
| Equity Growth % | - | 96.07% | -637.29% | 33.2% | 84.26% | 1003.98% |
| Book Value per Share | -137.23 | -5.40 | -39.82 | -16.00 | -0.58 | 0.43 |
| Total Shareholders' Equity | -71.58M | -2.82M | -20.76M | -13.87M | -2.18M | 11.46M |
| Common Stock | 0 | 1K | 1K | 5K | 2K | 3K |
| Retained Earnings | -71.72M | -76.31M | -88.5M | -114.73M | -139.56M | -148.81M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
ICU Cash Flow Statement
SeaStar Medical Holding Corporation (ICU) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | -5.57M | -5.11M | -7.79M | -10.29M | -16.01M | -16.01M |
| Operating CF Margin % | - | - | - | - | -11857.04% | - |
| Operating CF Growth % | - | 8.22% | -52.41% | -31.96% | -55.63% | 35.94% |
| Net Income | -3.28M | -4.6M | -12.19M | -26.23M | -24.83M | -13.66M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 1.31M | 1.93M | 887K | 476K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -3.19M | 162K | 533K | 11.14M | 6.94M | 498K |
| Working Capital Changes | 890K | -680K | 2.55M | 2.88M | 992K | -1.51M |
| Change in Receivables | 0 | 0 | 4K | 12K | -112K | -153K |
| Change in Inventory | 137K | 55K | 0 | 0 | 0 | -83K |
| Change in Payables | 225K | -297K | 1.55M | 2.44M | -1.28M | -1.45M |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 105.57M | 0 | 0 | 0 | 0 |
| Cash from Financing | 4.89M | 2.82M | 7.33M | 10.41M | 17.65M | 25.88M |
| Debt Issued (Net) | -133K | 2.82M | 3.48M | 3.53M | -4.41M | -21K |
| Equity Issued (Net) | 1000K | 0 | 1000K | 1000K | 1000K | 4M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -6.15M | 272K | 4.62M | 5.58M |
| Net Change in Cash | -680K▲ 0% | 471.61K▲ 169.4% | -463K▼ 198.2% | 129K▲ 127.9% | 1.64M▲ 1173.6% | 11.68M▲ 0% |
| Free Cash Flow | -5.57M▲ 0% | -5.11M▲ 8.2% | -7.79M▼ 52.4% | -10.29M▼ 32.0% | -16.01M▼ 55.6% | -14.2M▲ 0% |
| FCF Margin % | - | - | - | - | -11857.04% | -1611.58% |
| FCF Growth % | - | 8.22% | -52.41% | -31.96% | -55.63% | 10.13% |
| FCF per Share | -10.68 | -9.80 | -14.95 | -11.87 | -4.28 | -4.28 |
| FCF Conversion (FCF/Net Income) | 1.70x | 1.11x | 0.64x | 0.39x | 0.64x | 1.04x |
| Interest Paid | 1K | 0 | 6K | 1.13M | 553K | 30K |
| Taxes Paid | 1K | 0 | 1K | 0 | 3K | 0 |
ICU Key Ratios
SeaStar Medical Holding Corporation (ICU) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | - | -119.2% |
| Return on Invested Capital (ROIC) | - | - | - | - | 319.94% |
| Gross Margin | - | - | - | 100% | 95.35% |
| Net Margin | - | - | - | -18392.59% | -1551.08% |
| Debt / Equity | - | - | - | - | 0.00x |
| Interest Coverage | -20.99x | -18.43x | -13.15x | -73.12x | -209.88x |
| FCF Conversion | 1.11x | 0.64x | 0.39x | 0.64x | 1.04x |
| Revenue Growth | - | - | - | - | 1195.59% |
ICU Frequently Asked Questions
SeaStar Medical Holding Corporation (ICU) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
SeaStar Medical Holding Corporation (ICU) reported $0.9M in revenue for fiscal year 2024.
SeaStar Medical Holding Corporation (ICU) grew revenue by 0.0% over the past year. Growth has been modest.
SeaStar Medical Holding Corporation (ICU) reported a net loss of $13.7M for fiscal year 2024.
Dividend & Returns
SeaStar Medical Holding Corporation (ICU) had negative free cash flow of $14.2M in fiscal year 2024, likely due to heavy capital investments.
Explore More ICU
SeaStar Medical Holding Corporation (ICU) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates